Received Oct 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y013348 | OT |
No other AE; PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's; Information has been received from Business Partner/CRO on 31-Jul-2025. This spontaneous report was received from a/an Other health professional and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 18-Apr-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #y018157, expiration date: 29-Apr-2026) 0.5 mL. On 21-Apr-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #y018157, expiration date: 29-Apr-2026) 0.5 mL. On 28-Apr-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #y018157, expiration date: 29-Apr-2026) 0.5 mL. On 09-May-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #y018157, expiration date: 29-Apr-2026) 0.5 mL. The patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), for the treatment of Prophylaxis. On 18-Apr-2025, the patient experienced PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025. On 21-Apr-2025, the patient experienced PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025. On 28-Apr-2025, the patient experienced PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025. On 09-May-2025, the patient experienced PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025. At the reporting time, the outcome of PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025, PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025, PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025 and PROQUAD was administered to multiple patients on 18APR2025, 21APR2025, 28APR2025, 9MAY2025 after having experienced two TE's on 11APR2025 and 12APR2025 was unknown. The action taken with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live was reported as not applicable.
Sterile diluent